Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Arsenic Trioxide (Arsenol) in TP53-mutated Myeloid Malignancies
NCT06778187Phase 2Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in acute myeloid leukemia (AML), myelodysplastic neoplasms (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by The University of Hong Kong. Primary endpoint: Adverse events at 24 months. Started Feb 2025; status: recruiting.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic neoplasms (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT06778187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06778187.